Valuation : Insmed Incorporated

Market Cap 26.54B 22.89B 21.53B 19.62B 36.89B 2,518B 37.09B 255B 99.07B 1,281B 99.63B 97.47B 4,248B P/E 2026 *
-74.4x
P/E 2027 * 136x
Enterprise Value 25.9B 22.34B 21.02B 19.15B 36.01B 2,458B 36.2B 248B 96.71B 1,251B 97.26B 95.15B 4,147B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 8.79x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.25%
1 week-1.92%
Current month-0.25%
1 month+23.24%
3 months+14.60%
6 months-18.63%
Current year-30.18%
1 week 117.15
Extreme 117.15
126.1
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
8/6/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.92%-10.72%+436.70% 26.54B
-0.25%-4.10%+38.38%+92.61% 68.21B
+0.95%-0.36%+47.59%+88.33% 64.25B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.16%+0.56%+31.42%-18.48% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
+0.42%-6.91%+275.58%+195.92% 11.69B
Average +0.08%-4.22%+68.42%+202.99% 27.48B
Weighted average by Cap. +0.12%-3.38%+51.54%+160.10%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.47B 1.34B 2.51B 171B 2.52B 17.33B 6.74B 87.21B 6.78B 6.64B 289B 2.89B 2.49B 2.34B 2.13B 4.01B 274B 4.03B 27.68B 10.78B 139B 10.84B 10.6B 462B
Net income -349M -301M -283M -258M -486M -33.16B -488M -3.35B -1.3B -16.87B -1.31B -1.28B -55.93B 211M 182M 172M 156M 294M 20.07B 295M 2.03B 789M 10.21B 794M 777M 33.85B
Net Debt -632M -545M -513M -467M -878M -59.96B -883M -6.06B -2.36B -30.5B -2.37B -2.32B -101B -1.16B -998M -938M -855M -1.61B -110B -1.62B -11.09B -4.32B -55.84B -4.34B -4.25B -185B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-09-01 US$121.51 -0.25% 1,419,286
26-08-31 US$121.82 +2.77% 2,390,325
26-08-28 US$118.54 -2.35% 1,977,867
26-08-27 US$121.39 -2.41% 1,056,260
26-08-26 US$124.39 +0.40% 1,979,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
121.51USD
Average target price
200.18USD
Spread / Average Target
+64.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock